North America Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023-2029

The North America Motion Sickness Treatment Market should witness market growth of 2.5% CAGR during the forecast period (2023-2029).

The market's growth is anticipated to be propelled by untapped, emerging markets with high potential, owing to the presence of enhanced healthcare infrastructure, rising unmet healthcare demands, and a surge in need for efficient motion sickness medication.

Furthermore, certain demographics may be more susceptible to motion sickness symptoms, such as expectant mothers and individuals between the ages of 2 and 12. The initial indications of motion sickness encompass queasiness, heightened salivation, burping, perspiration, hyperventilation, and a general sense of discomfort. Motion sickness can be prevented or treated through pharmacological therapies such as anticholinergic drugs, antihistaminic drugs, and various other medications.

The North American over-the-counter drugs sector is experiencing growth due to the rising trend of individuals choosing OTC drugs for minor complications instead of seeking intensive treatment from healthcare professionals. This trend is particularly prevalent in countries such as the U.S., Canada, and Mexico. Furthermore, the emergence of numerous mid-size and small players in the region has led to the introduction of innovative medications at reduced prices, thereby enhancing the over-the-counter drugs sector in the region. The wider usage of OTC, like antihistamines, by general consumers for various minor health issues like motion sickness is expected to propel the motion sickness treatment market growth in the region.

The US market dominated the North America Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $131.6 Million by 2029. The Canada market is poised to grow at a CAGR of 4.5% during (2023-2029). Additionally, The Mexico market should witness a CAGR of 4.3% during (2023-2029).

Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).

Scope of the Study

By Drug Class

• Antihistamines
• Anticholinergics
• Others

By Route of Administration

• Oral
• Others

By Distribution Channel

• Drug Store & Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Viatris, Inc.
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals, Inc.
• Baxter International, Inc.
• Novartis AG
• Abbott Laboratories
• Sun Pharmaceutical Industries Ltd.
• Zydus Lifesciences Ltd.
• Prestige Consumer Healthcare, Inc.
• WellSpring Pharmaceutical Corporation (Avista Capital Partners)

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free